MedPath
NMPA Approval

Risankizumab Injection (Subcutaneous Injection)

国药准字SJ20250008

March 4, 2025

Drug Information

利生奇珠单抗注射液(皮下注射)

喜开悦

注射剂

360 mg(2.4 mL)/支

生物制品

March 4, 2025

March 3, 2030

Company Information

Applicant Company

艾伯维公司

1 N Waukegan Rd, North Chicago, IL 60064 United States of America

Manufacturing Company

PATHEON ITALIA SPA

Viale Gian Battista Stucchi 110, Monza, Monza e Brianza 20900 ITALY

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

利生奇珠单抗注射液(皮下注射) - NMPA 批准文号 | MedPath